Başkent Üniversitesi Yayınları

Permanent URI for this communityhttps://hdl.handle.net/11727/13092

Browse

Search Results

Now showing 1 - 9 of 9
  • Item
    Gender-Based Analysis of Outcome After Heart Transplantation
    (Başkent Üniversitesi, 2012-08) Eifert, Sandra; Meiser, Bruno; Kaczmarek, Ingo; Beiras-Fernandez, Andres; Bigdeli, Amir Khosrow; Horster, Sophia; Nickel, Thomas; Kofler, Sieglinde
    Objectives: Gender differences between donors and recipients might have an effect on outcome after heart transplantation. Literature and registries reveal controversial results. We reviewed 1000 heart transplantations at our center focusing on the influence of gender differences on short- and long-term outcome after heart transplantation. Materials and Methods: We performed a retrospective analysis of 1000 (960 primary and 40 redo-heart transplantations) between August 1981 and July 2008. In contrast to other studies, the data for gender differences (donor gender and recipient gender) were evaluated for recipient survival and survival conditional to early mortality. Results: Female donors are significantly older than male donors (females, 36.5 ± 14.5 years; males, 31.2 ± 13.8 years). One-year survival was significantly inferior in male recipients receiving female donor hearts (mR/fD: 73.7%) compared to females receiving male donor organs (fR/mD: 90.9%) (P = .045). Univariate analysis revealed that, for recipients who survived > 1 year, survival at 10 years was significantly greater for female donors and female recipients (90%) than it was for male donors and male recipients (72%; P = .034). Multivariate analysis showed that the gender combination with female donors and female recipients was an independent indicator for greater long-term survival (P = .04). Conclusions: The gender combination of female donors and male recipients had a greater risk for early mortality after heart transplantation, and the combination of male donors and female recipients resulted in favorable short-term outcomes. In long-term follow-up, recipients of hearts from female donors had better survival, especially female recipients.
  • Item
    ECMO After Prolonged Cardiopulmonary Resuscitation as a Successful Bridge to Immediate Cardiac Retransplant in a 6-Year-Old Girl
    (Başkent Üniversitesi, 2012-04) Bigdeli, Amir Khosrow; Kaczmarek, Ingo; Sodian, Ralf; Schmitz, Christoph; Michel, Sebastian; Beiras-Fernandez, Andres; Deutsch, Marcus-André
    Heart failure, life-threatening arrhythmias, and sudden cardiac death are common complications in patients with advanced chronic cardiac allograft rejection—the major limiting factor of long-term survival after heart transplant. In patients with sustained cardiorespiratory arrest refractory to cardiopulmonary resuscitation extracorporeal membrane oxygenation therapy is a therapeutic option. We report the case of a 6-year-old girl with severe chronic allograft vasculopathy who was successfully bridged to cardiac retransplant through extracorporeal membrane oxygenation therapy after prolonged cardiopulmonary resuscitation. Our case demonstrates extracorporeal membrane oxygenation as a rescuing therapeutic option in high-risk, bridge-to-transplant patients, with cardiac arrest. Even after prolonged cardiopulmonary resuscitation, there were no neurologic events, and our patient recovered without any neurologic damage.
  • Item
    Combination Antifungal Therapy for Invasive Pulmonary Aspergillosis in a Heart Transplant Recipient
    (Başkent Üniversitesi, 2011-08) Beiras-Fernandez, Andres; Kaczmarek, Ingo; Reichart, Bruno; Ueberfuhr, Peter; Michel, Sebastian; Nickel, Thomas; Bigdeli, Amir K.
    Invasive pulmonary aspergillosis is a severe complication after solid organ transplant, with a high mortality rate. We present a 45-year-old male heart transplant recipient who developed fever, progressive worsening of dyspnea, and productive cough without response to antibiotics. Diagnosis of invasive pulmonary aspergillosis was made based on clinical, laboratory, and radiographic findings. The patient was treated successfully with combined antifungal therapy (voriconazole and micafungin). This case report highlights the importance of a high degree of clinical suspicion to allow curative treatment of invasive aspergillosis and the efficiency of new antifungal drugs.
  • Item
    Extracorporeal Membrane Oxygenation Bridging to Lung Transplant Complicated by Heparin-Induced Thrombocytopenia
    (Başkent Üniversitesi, 2010-12) Dolch, Michael E.; Munich Lung Transplant Group; Irlbeck, Michael; Behr, Jürgen; Beiras-Fernandez, Andres; Überfuhr, Peter A.; Hatz, Rudolf; Frey, Lorenz
    In patients with acute respiratory failure and life-threatening impairment of pulmonary gas exchange, venovenous extracorporeal membrane oxygenation offers further therapeutic options. During extracorporeal membrane oxygenation treatment, systemic anticoagulation is usually achieved by heparin administration, which exposes patients to the risk of heparin-induced thrombocytopenia type II. We present a patient with acute respiratory distress syndrome on venovenous extracorporeal membrane oxygenation who experienced heparin-induced thrombocytopenia type II and in whom anti­coagulation was continued with argatroban. Because respiratory failure did not resolve, the patient was bridged to lung transplant with extracorporeal membrane oxygenation. Argatroban anticoagulation was safely used until lung transplant (on day 114 after extracorporeal membrane oxygenation initiation) and after transplant in the presence of hepatic failure.
  • Item
    Influence of Hypothermia and Cardioplegic Solutions on Expression of α-Gal Epitope on Porcine Aortic Endothelial Cells
    (Başkent Üniversitesi, 2010-09) Keller, Miriam; Brenner, Paolo; Reichart, Bruno; Schmoeckel, Michael; Beiras-Fernandez, Andres
    bjectives: The Galα1-3Galβ1-4GlcNAc-R is the major antigen on pig tissue bound by human xenoreactive natural antibodies in xeno­transplant. We have investigated in vitro the influence of hypothermic storage with cardioplegic solutions on expression of Galα1-3Galβ1-4GlcNAc-Rs and hyperacute xenograft rejection. Materials and Methods: To analyze effects of hypothermia on the Galα1-3Galβ1-4GlcNAc-Rs, cultured porcine aortic endothelial cells were exposed to a temperature of 4°C for 1 hour, 4 hours, and 6 hours. Cell cultures of the control groups were incubated at the same time at 38°C. To investigate the influence of cardioplegic solutions on the Galα1-3Galβ1-4GlcNAc-Rs, porcine aortic endothelial cells were exposed to 4°C for 4 hours in the presence of University of Wisconsin solution or histidine-tryptophan-ketoglutarate solution. Cells of the control groups were cooled at 4°C for 4 hours without cardioplegic solution. After treatment, porcine aortic endothelial cells were submitted to fluorescence-activated cell sorter. Results: Hypothermia of 4°C showed no significant effect on the quantity of Galα1-3Galβ1-4GlcNAc-Rs. However, the treatment of porcine aortic endothelial cells with University of Wisconsin solution resulted in a highly significant reduction of Galα1-3Galβ1-4GlcNAc-Rs by 50% (P = .006). Treatment of porcine aortic endothelial cells with histidine-tryptophan-ketoglutarate solution decreased α-Gal quantity significantly by 32% (P = .011). Conclusions: Our data offer new perspectives in the prevention of hyperacute, humoral xenograft rejection by reducing the Galα1-3Galβ1-4GlcNAc-Rs after exposure to different cardioplegic solutions.
  • Item
    Off-Pump Coronary Surgery for Allograft Vasculopathy 8 Years After Heart Transplant
    (Başkent Üniversitesi, 2009-12) Michel, Sebastian; Vicol, Calin; Reichart, Bruno; Abicht, Jan; Ueberfuhr, Peter; Beiras-Fernandez, Andres; Kaczmarek, Ingo
    Cardiac allograft vasculopathy is a severe complication after heart transplant, and is the major cause of death in patients surviving 1 year after transplant. We present a 59-year-old patient undergoing off-pump, coronary artery bypass surgery, 8 years after heart transplant. Owing to toxic liver disease, the lipid lowering therapy with statins had to be stopped 6 years after transplant, and coronary artery disease developed rapidly within 2 years. Off-pump, coronary bypass surgery was performed using a new, multisuction cardiac positioner; a disposable stabilizer; and a proximal seal system to avoid clamping of the aorta. The patient received 3 bypass grafts: the left internal thoracic artery; to the left anterior descending coronary artery; 1 saphenous vein graft to the marginal branch of the circumflex artery; and 1 saphenous vein graft to the right coronary artery. His postoperative course was uneventful.
  • Item
    Donor-Specific HLA Alloantibodies: Long-Term Impact on Cardiac Allograft Vasculopathy and Mortality After Heart Transplant
    (Başkent Üniversitesi, 2008-09) Kaczmarek, Ingo; Ueberfuhr, Peter; Spannagl, Michael; Reichart, Bruno; Sodian, Ralf; Vicol, Calin; Schmoeckel, Michael; Beiras-Fernandez, Andres; Kauke, Teresa; Deutsch, Marcus-André
    Objectives: The clinical significance of anti-HLA-alloantibodies remains controversial. Recent studies have linked development of donor-specific HLA-antibodies to chronic allograft rejection and graft loss after heart, kidney, and lung transplants. We investigated the clinical impact of donor-specific humoral alloreactivity during the follow-up of heart transplant recipients. Patients and Methods: The sera of 213 heart transplant recipients were screened by enzyme-linked immunosorbent assay for HLA-antibody production. The antigen specificity of the detected HLA class I and class II antibodies was identified using a Luminex assay. Outcome variables were survival, cardiac allograft vasculopathy, and cellular rejection. Results: The cumulative incidence of alloantibody formation was 23/213 patients (10.8%). The majority of detected alloantibodies were donor-specific for HLA class II. Mean follow-up at antibody measurements was 7 ± 4.9 years. Freedom from vasculopathy at 5 and 10 years was 77.9% and 26% in donor-specific HLA-antibody-positive patients compared with 84.6% and 65.2% in antibody-negative controls (P = .025). Freedom from treated, biopsy-proven rejection was 44.4% for donor-specific HLA-antibody-positive patients compared with 70.2% in the controls (P = .06). Multivariate analyses identified donor-specific HLA antibody positivity as an independent risk factor for vasculopathy. Conclusions: Our results demonstrate a strong correlation between the development of donor-specific HLA antibodies and adverse outcomes after heart transplant. Detection of donor-specific HLA antibodies might identify high-risk patients and offer an opportunity for early clinical intervention and modification of immunosuppression.
  • Item
    Novel Treatment with Rituximab of Oropharyngeal Posttransplant Lymphoproliferative Disorder after Heart Transplantation
    (Başkent Üniversitesi, 2005-12) Kaczmarek, Ingo; Beiras-Fernandez, Andres; Sadoni, Sebastian; Bengel, Dominik; Deutsch, Marcus-Andre; Meiser, Bruno; Reichart, Bruno
    Posttransplant lymphoproliferative disorders are severe complications that arise after solid organ transplantation, which are often related to Epstein-Barr virus. Reports are anecdotal, and a standardized therapy does not exist. We report a case of a 36-year-old man who developed posttransplant lymphoproliferative disorder of the oropharynx 1 year after receiving a heart transplant. A short review of the literature is presented, after which a new therapeutic approach that combines antiviral therapy, monoclonal antibodies, and a sirolimus-based maintenance immunosuppression regimen with reduced target trough levels of tacrolimus is introduced. The patient achieved complete remission and was free from recurrence 18 months after the therapy was initiated.
  • Item
    In Vitro Influence of Polyclonal Anti-Thymocyte Globulins on Leukocyte Expression of Adhesion Molecules
    (Başkent Üniversitesi, 2005-12) Beiras-Fernandez, Andres; Walther, Sebastian; Kaczmarek, Ingo; Ngo, Truc; Muenzing, Silvia; Hammer, Claus; Thein, Eckart
    Objectives: Polyclonal anti-thymocyte globulins (ATGs) are drugs used in the induction of immunosuppression, in the treatment of acute rejection, and in the therapy of hematologic disorders. Treatment with ATGs can produce adverse effects due to cross-reacting antibodies directed against nonmyeloid cells. This study sought to evaluate the interaction of ATGs and some adhesion molecules expressed on the surface of neutrophils and lymphocytes. Materials and Methods: We determined the effects of different doses of 3 polyclonal ATGs on the activation and expression of lymphocyte and neutrophil adhesion molecules in whole blood by means of flow cytometry. Results: ATG treatment reduced the percentage of lymphocytes gated for CD18 and CD62L, as well as the expression of CD11b, CD18, and CD62L in a dose-dependent manner. ATGs modulated the percentage of gated neutrophils for CD18. Although ATG treatment did not affect CD11b or CD62L gating in neutrophils, it did regulate expression of these adhesion markers. Conclusions: Our results show that ATGs can modify the expression levels of some of the main leukocyte adhesion molecules that are responsible for the characteristic cellular adhesion after ischemia/ reperfusion. These properties of ATGs may contribute to reduced leukocyte infiltration after solid-organ transplantation.